NEONC TECHNOLOGIES HOLDINGS, INC. Files Amendment to S-1 Registration Statement

TL;DR

<b>NEONC TECHNOLOGIES HOLDINGS, INC. has filed an amendment to its S-1 registration statement, indicating progress towards a public offering.</b>

AI Summary

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed a Amended IPO Registration (S-1/A) with the SEC on January 16, 2024. NEONC TECHNOLOGIES HOLDINGS, INC. filed an S-1/A amendment on January 16, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90069. The filing is related to a registration statement under the Securities Act of 1933, with registration number 333-276124. NEONC TECHNOLOGIES HOLDINGS, INC. is classified under Standard Industrial Classification code 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking NEONC TECHNOLOGIES HOLDINGS, INC., this filing contains several important signals. This S-1/A filing signifies a step forward in NEONC TECHNOLOGIES HOLDINGS, INC.'s process to become a publicly traded company, potentially allowing for capital infusion and increased liquidity. The amendment provides updated information for potential investors regarding the company's structure, operations, and regulatory compliance as it prepares for an IPO.

Risk Assessment

Risk Level: low — NEONC TECHNOLOGIES HOLDINGS, INC. shows low risk based on this filing. The filing is an S-1/A, which is an amendment to a registration statement, indicating it's part of an ongoing process rather than a new event with immediate financial implications.

Analyst Insight

Monitor for the effectiveness of the registration statement and subsequent IPO details to assess investment potential.

Key Numbers

• 2024-01-16 — Filing Date (Date of S-1/A filing)
• 333-276124 — Registration Number (SEC registration number for the offering)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
• 1231 — Fiscal Year End (Company's fiscal year end date)
• 90069 — ZIP Code (Business address ZIP code)
• 310 663 7831 — Business Phone (Company's business phone number)

Key Players & Entities

• NEONC TECHNOLOGIES HOLDINGS, INC. (company) — Registrant name
• Dr. Thomas C. Chen (person) — Chief Executive Officer
• Thomas J. Poletti, Esq. (person) — Copies To
• Veronica Lah, Esq. (person) — Copies To
• Manatt, Phelps & Phillips LLP (company) — Legal counsel
• Mitchell S. Nussbaum, Esq. (person) — Copies To
• Angela M. Dowd, Esq. (person) — Copies To
• Loeb & Loeb LLP (company) — Legal counsel

Forward-Looking Statements

• NEONC TECHNOLOGIES HOLDINGS, INC. will complete its initial public offering (IPO) within the next 6-12 months. (NEONC TECHNOLOGIES HOLDINGS, INC.) — medium confidence, target: 2025-01-12
• The company will utilize the proceeds from the offering to advance its pharmaceutical pipeline. (NEONC TECHNOLOGIES HOLDINGS, INC.) — high confidence, target: 2025-01-12

FAQ

Industry Context

The company operates within the Pharmaceutical Preparations industry (SIC code 2834), which involves the manufacturing of drugs and medicines.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed business operations, financial information, and risk factors.
2. Track subsequent filings for updates on the registration statement's effectiveness and potential IPO launch.
3. Research the company's management team and legal counsel involved in the filing.

Key Dates

• 2024-01-16: Filing of Amendment No. 1 to Form S-1 Registration Statement — Indicates progress in the company's registration process for public offering.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previously filed registration statement, indicating updates or corrections to the initial filing.

Key Financial Figures

• $90,462 — 30, 2023 have only generated revenue of $90,462. We do not anticipate generating signif
• $8,765,816 — foreseeable future. We had net loss of $8,765,816 for the nine months ended September 30,
• $3,046,757 — ine months ended September 30, 2023 and $3,046,757 for the year ended December 31, 2022. A
• $32,554,732 — 2023, we had an accumulated deficit of $32,554,732. Market Opportunity The World Healt
• $166.5 billion — et is estimated to grow at 9.4% CAGR to $166.5 billion by 2028 and the global brain tumor drug
• $4.4 billion — drug market to grow at CAGR of 9.0% to $4.4 billion by 2029. iHeathcareAnalys has reporte
• $2.3 billion — et is expected to grow at 12.7% CAGR to $2.3 billion by 2029. According to the book, Gliobla
• $1.235 billion — ing growth company if we have more than $1.235 billion in annual revenue, we have more than $7
• $700 million — on in annual revenue, we have more than $700 million in market value of our stock held by no
• $1 billion — ort on Form 10-K) or we issue more than $1 billion of non-convertible debt securities over

Filing Documents

• neonctechnologies_s1a.htm (S-1/A) — 2762KB
• neonctechnologies_ex10-14.htm (EX-10.14) — 124KB
• neonctechnologies_ex10-15.htm (EX-10.15) — 125KB
• neonctechnologies_ex10-16.htm (EX-10.16) — 124KB
• neonctechnologies_ex10-17.htm (EX-10.17) — 59KB
• neonctechnologies_ex10-18.htm (EX-10.18) — 64KB
• neonctechnologies_ex10-19.htm (EX-10.19) — 60KB
• neonctechnologies_ex10-20.htm (EX-10.20) — 63KB
• neonctechnologies_ex10-21.htm (EX-10.21) — 63KB
• neonctechnologies_ex10-22.htm (EX-10.22) — 59KB
• neonctechnologies_ex10-23.htm (EX-10.23) — 60KB
• neonctechnologies_ex10-24.htm (EX-10.24) — 60KB
• neonctechnologies_ex23-2.htm (EX-23.2) — 3KB
• neonctechnologies_ex107.htm (EX-FILING FEES) — 20KB
• img_001.jpg (GRAPHIC) — 147KB
• img_002.jpg (GRAPHIC) — 61KB
• img_003.jpg (GRAPHIC) — 44KB
• img_004a.jpg (GRAPHIC) — 77KB
• img_004c.jpg (GRAPHIC) — 112KB
• img_004d.jpg (GRAPHIC) — 112KB
• img_004b.jpg (GRAPHIC) — 50KB
• img_005.jpg (GRAPHIC) — 9KB
• img_009.jpg (GRAPHIC) — 25KB
• img_010.jpg (GRAPHIC) — 23KB
• img_011.jpg (GRAPHIC) — 19KB
• img_012.jpg (GRAPHIC) — 10KB
• img_014.jpg (GRAPHIC) — 5KB
• img_015.jpg (GRAPHIC) — 22KB
• img_016.jpg (GRAPHIC) — 16KB
• img_017.jpg (GRAPHIC) — 30KB
• img_018.jpg (GRAPHIC) — 39KB
• img_019.jpg (GRAPHIC) — 31KB
• img_020.jpg (GRAPHIC) — 33KB
• img_021.jpg (GRAPHIC) — 30KB
• img_022.jpg (GRAPHIC) — 31KB
• img_023.jpg (GRAPHIC) — 45KB
• 0001829126-24-000192.txt (&nbsp;) — 4983KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS 78

USE OF PROCEEDS

USE OF PROCEEDS 80 DIVIDEND POLICY 81 CAPITALIZATION 82

DILUTION

DILUTION 83 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 85

BUSINESS

BUSINESS 103 MANAGEMENT 156 PRINCIPAL SHAREHOLDERS 169 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 171

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 175 SHARES ELIGIBLE FOR FUTURE SALE 179

UNDERWRITING

UNDERWRITING 181 LEGAL MATTERS 188 EXPERTS 188 WHERE YOU CAN FIND ADDITIONAL INFORMATION 188 i Table of Contents Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we nor the underwriters take responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Through and including ____, 2024 (the 25 th day after the date of this prospectus), all dealers that buy, sell or trade in our common shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. For investors outside of the United States neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about, and to observe any restrictions relating to, this offering and the distribution of this prospectus outside of the United States. See the section of this prospectus entitled &ldquo; Underwriting &rdquo; for additional information on these restrictions. Unless otherwise indicated, information in this prospectus concerning economic conditions, our industries and our markets is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. This information involves a number of

View Full Filing

View this S-1/A filing on SEC EDGAR